CALGARY, Alberta, March 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, in connection with its upcoming annual and special meeting of shareholders to be held on March 24, 2026 (the “Meeting”), three new director nominees will be proposed for election in the place of three of the curr ...